1. India Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Gkb Ophthalmics Limited

Gkb Ophthalmics Limited

57.17
INR
-2.65
(-4.43%)
10.92EPS
9.81P/E
317.56MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
99.8
84.52
105.35
178.36
185.1
123.18
115.68
111.97
140.35
149.54
175.07
216.2
295.7
296.54
Basic EPS, GAAP
9.61
0.01
9.51
6.23
-2.34
-2.38
-3.65
-1.8
2.53
-0.33
-5.58
-13.98
2.42
6.42
Free Cash Flow per Basic Share
13.29
15.81
-35.16
-23.41
-10.93
8.44
-1.18
1.04
0.62
-7.91
4.25
-11.06
-9.59
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
96.06
96.33
107.89
112.64
108.2
118.1
117.55
124.3
125.18
124.38
118.58
103.24
104.82
- -
Tangible Book Value per Share
95.78
96.09
107.71
110.75
106.38
116.48
116.06
122.82
125.17
124.37
118.58
103.24
104.45
- -
Basic Weighted Avg Shares
4
4
4
4
4
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
415
351
438
741
769
572
583
564
707
754
883
1,090
1,491
1,498
Operating Margin (%)
15.45
-3.45
-4.7
1.58
-0.45
-4.19
-2.54
-1.41
3.3
1.18
-2.62
-5.19
3.62
4.66
Depreciation Expense
12
16
15
14
17
35
36
31
27
28
29
31
32
32
Net Income, GAAP
40
- -
40
26
-10
-11
-18
-9
13
-2
-28
-70
12
32
Effective Tax Rate (%)
46.06
- -
49.98
12.12
- -
- -
- -
- -
0.12
16.57
- -
- -
2.47
3.45
Profit Margin (%)
9.63
0.01
9.03
3.49
-1.26
-1.93
-3.15
-1.61
1.8
-0.22
-3.18
-6.46
0.82
2.17
Working Capital
133
126
285
295
274
268
314
359
368
424
413
370
368
- -
LT Debt
15
5
1
1
- -
- -
- -
10
16
12
11
31
16
- -
Total Equity
399
400
448
468
449
548
593
663
674
673
642
564
549
- -
Return on Invested Capital (%)
3.68
- -
6.65
4.08
- -
- -
- -
- -
3.17
1.01
- -
- -
6.79
- -
Return on Capital (%)
10.45
- -
9.19
6.62
- -
- -
- -
- -
2.18
0.8
- -
- -
1.73
- -
Return on Common Equity (%)
10.66
0.01
9.32
5.65
-2.12
-2.21
-3.23
-1.49
2.03
-0.27
-4.59
-12.6
2.32
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
101
- -
LT Borrowings
- -
16
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
258
265
318

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,080
- -
Cash, Cash Equivalents & STI
- -
44
- -
Accounts Receivable, Net
- -
449
- -
Inventories
- -
546
- -
Total Current Liabilities
- -
712
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
101
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.45%
-3.59%
-2.74%
Free Cash Flow
-252.79%
-390.35%
-13.33%
Net Income, GAAP
111.64%
251.74%
-117.3%
Sales/Revenue/Turnover
15.55%
21.85%
36.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
260
261
258
310
1,090
2026
323
302
568
298
1,491
2027
330
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.5
-2.41
-4.03
-7.03
-13.98
2026
-2.02
3.17
0.88
0.38
2.42
2027
2
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Krishna Gopal Gupta
Full Time Employees
156
Sector
Health technology
Industry
Medical specialties
Address
16-A, Tivim Industrial Estate Mapusa GO India 403526
IPO Date
Apr 22, 1996
Website
gkb.net
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
GKB Ophthalmics Limited manufactures and sells unfinished ophthalmic lenses, primarily semi-finished organic and mineral lenses including single vision lenses such as 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change, 1.50 Q-Shade+, and 1.50 SunSensor; bifocal lenses including 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change, and 1.50 Q-Shade+; progressive lenses including 1.498 CR-39, 1.50 Blucheck, 1.56 DayNite, and 1.56 DayNite Fast Change; aspheric lenses including 1.498 CR-39; as well as bifocal glass moulds and other optical products. The company, founded in 1981 and headquartered at 16-A Tivim Industrial Estate, Mapusa, Goa, India, operates as a 100% export-oriented unit with products shipped to various countries worldwide and maintains subsidiaries including GKB Ophthalmics Products FZE in the UAE, GSV Ophthalmics Private Limited in Goa, Prescription Optical Products LLC in Dubai, and step-down subsidiary Lensco in New Jersey, USA. Recent developments include reporting consolidated net sales of Rs 32.31 crore for the quarter ended June 2025, marking the highest quarterly sales in five quarters with a 26.83% growth over nine months to Rs 93.50 crore, alongside a consolidated net profit of Rs 1.60 crore for the quarter ended September 2025 with sales up 15.42% to Rs 30.17 crore; ongoing investments in joint venture GSV Ophthalmics Private Limited for high refractive index lenses with a Korean partner; approval of material related party transactions and increased borrowing limits at the 43rd AGM in August 2025; and operational enhancements evidenced by improved debtors turnover ratio of 4.28 times.